Ausgabe 4/2009
Inhalt (24 Artikel)
Temozolomide in malignant gliomas: current use and future targets
J. Lee Villano, Tara E. Seery, Linda R. Bressler
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
Jeeyun Lee, Kyung Hae Jung, Young Suk Park, Joong Bae Ahn, Sang Jun Shin, Seock-Ah Im, Do Youn Oh, Dong Bok Shin, Tae Won Kim, Namsu Lee, Jae Ho Byun, Yong Sang Hong, Joon Oh Park, Se Hoon Park, Ho Yeong Lim, Won Ki Kang
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study
Mark P. Saunders, Richard Wilson, Marc Peeters, Robert Smith, Alex Godwood, Stuart Oliver, Eric Van Cutsem
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer
Franco Nolè, D. Crivellari, R. Mattioli, G. Pinotti, P. Foa, E. Verri, R. Fougeray, M. Brandely, A. Goldhirsch
The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties
Carl F. Beyer, Nan Zhang, Richard Hernandez, Danielle Vitale, Thai Nguyen, Semiramis Ayral-Kaloustian, James J. Gibbons
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
Joshua Ö. Haznedar, Shem Patyna, Carlo L. Bello, Geoffrey W. Peng, William Speed, Xiaoming Yu, Qingling Zhang, Juthamas Sukbuntherng, David J. Sweeny, Lida Antonian, Ellen Y. Wu
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
Gyeong-Won Lee, Hye Jung Kim, Ji-Hyun Ju, Seok-Hyun Kim, Hoon Gu Kim, Tae Hyo Kim, Hyun Jin Kim, Chi-Young Jeong, Jung Hun Kang
Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells
Takeshi Asano, Arisa Tsutsuda-Asano, Yoshitaka Fukunaga
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Andrew Conroy, David E. Stockett, Duncan Walker, Michelle R. Arkin, Ute Hoch, Judith A. Fox, Rachael Elizabeth Hawtin
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma
Pooja Hingorani, Wendong Zhang, Sajida Piperdi, Leyna Pressman, Juan Lin, Richard Gorlick, E. Anders Kolb
Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
Charles O. Noble, Zexiong Guo, Mark E. Hayes, James D. Marks, John W. Park, Christopher C. Benz, Dmitri B. Kirpotin, Daryl C. Drummond
Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice
Naomi Nakashima-Kamimura, Takashi Mori, Ikuroh Ohsawa, Sadamitsu Asoh, Shigeo Ohta
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen
Paul Ruff, D. A. Vorobiof, J. P. Jordaan, G. S. Demetriou, S. D. Moodley, A. L. Nosworthy, I. D. Werner, J. Raats, L. J. Burgess
Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Alba A. Brandes, A. Tosoni, E. Franceschi, V. Blatt, A. Santoro, M. Faedi, P. Amistà, M. Gardiman, R. Labianca, C. Bianchini, M. Ermani, M. Reni
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K. Ramanathan, Chandra P. Belani, Deepti A. Singh, Michael Tanaka, Heinz-Josef Lenz, Yun Yen, Hedy L. Kindler, Syma Iqbal, Jeff Longmate, Philip C. Mack, Georg Lurje, Regina Gandour-Edwards, Janet Dancey, David R. Gandara
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer
Vasiliki Bozionelou, Kostas Kalbakis, Lambros Vamvakas, Sofia Agelaki, Nikolaos Androulakis, Antonia Kalykaki, Vassilis Georgoulias, Dimitris Mavroudis
Pro-apoptotic and cytostatic activity of naturally occurring cardenolides
Elena Bloise, Alessandra Braca, Nunziatina De Tommasi, Maria Antonietta Belisario
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Anna C. Pavlick, Jennifer Wu, John Roberts, Mark A. Rosenthal, Anne Hamilton, Scott Wadler, Kathleen Farrell, Michelle Carr, David Fry, Anthony J. Murgo, Ruth Oratz, Howard Hochster, Leonard Liebes, Franco Muggia
Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts
Vilma A. Sardão, Paulo J. Oliveira, Jon Holy, Catarina R. Oliveira, Kendall B. Wallace
Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents
Lee Roy Morgan, Robert F. Struck, William R. Waud, Blaise LeBlanc, Andrew H. Rodgers, Branko S. Jursic
Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane
Sabry M. Attia, Alaa A. Al-Anteet, Nouf M. Al-Rasheed, Abdulqader A. Alhaider, Mohammed M. Al-harbi
Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity
Johnson J. Liu, Stephen M. F. Jamieson, Joshuan Subramaniam, Virginia Ip, Nancy N. Jong, Julian F. B. Mercer, Mark J. McKeage
Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation
Agustin Cornejo, Mary Bohnenblust, Catherine Harris, Gregory A. Abrahamian